Canadian Agency Favors Zolgensma Only for Babies Up to 6 Months Old

Canadian Agency Favors Zolgensma Only for Babies Up to 6 Months Old

308312

Canadian Agency Favors Zolgensma Only for Babies Up to 6 Months Old

The Canadian Agency for Drugs and Technologies in Health (CADTH) will not recommend reimbursement for Zolgensma in children with spinal muscular atrophy (SMA) who are more than 6 months old, citing insufficient evidence of efficacy and safety in older patients. “Other countries are providing guidance and funding based on same evidence. Doctors and patients need guidance from a capable assessor,” the Canada Organization for Rare Disorders (CORD) said in response posted on Twitter. “If CADTH can’t figure…

You must be logged in to read/download the full post.